Drug Discovery to ensure the world is prepared for the next pandemic

READDI’s Antiviral Drug Discovery Center (AViDD Center) is a public-private partnership designed to identify and develop oral antivirals that can combat pandemic-level viruses.

Committed to Open Science

More

Accelerating Research

More

  • 40 Principal Investigators
  • 23 Research Sites
  • 29 Publications

Latest News

  • 01.15.25 Drug discovery efforts are producing promising antiviral compounds and academic innovation is the key More
  • 12.12.24 Antiviral Researchers at University of North Carolina at Chapel Hill READDI Speed Drug Discovery with CDD Vault More
  • 11.26.24 Novel oral drug in READDI-AC halts SARS-CoV-2 replication and improves outcomes in preclinical studies More

The devastating effects of the SARS-CoV-2 pandemic illustrates the critical need for new antiviral treatments – the collaborative coalition of READDI-AC is focused on addressing this need head-on.”

Developing oral broad spectrum direct acting antivirals,
effective against families of
high priority viral pathogens.

Who We Are